Successful Treatment with Rituximab in a Patient with Stiff-Person Syndrome Complicated by Dysthyroid Ophthalmopathy

Nagaaki Katoh, Masayuki Matsuda, Wataru Ishii, Hiroshi Morita and Shu-ichi Ikeda

Abstract

We report a patient with stiff-person syndrome and insulin-dependent diabetes mellitus with anti-glutamic acid decarboxylase (GAD) antibody, who suddenly complained of diplopia due to dysthyroid ophthalmopathy. Therapeutic efficacy of plasmapheresis and high-dose intravenous immunoglobulin was transient. After starting administration of rituximab, the patient showed obvious improvement of muscle spasms due to stiff-person syndrome and ophthalmoplegia following quick depletion of CD20-positive cells in peripheral blood. The anti-GAD and anti-thyroid antibodies decreased slowly. This drug might be a potent therapeutic option for refractory patients with stiff-person syndrome, particularly in those associated with dysthyroid ophthalmopathy.

Key words: stiff-person syndrome, dysthyroid ophthalmopathy, anti-glutamic acid decarboxylase (GAD) antibody, rituximab


Introduction

Stiff-person syndrome (SPS) is a rare intractable disorder characterized clinically by progressive rigidity and episodic sudden-onset muscle spasms with frequent association of insulin-dependent diabetes mellitus (DM) and chronic thyroid disorders (1). The anti-glutamic acid decarboxylase (GAD) antibody plays an important role in the pathogenesis by affecting the synaptic transmission of inhibitory neurons, and SPS has come to be recognized as a B-cell-mediated autoimmune disorder of the central nervous system (1-3). To ameliorate clinical symptoms due to SPS, therefore, immunomodulatory therapies targeting the anti-GAD antibody, such as plasmapheresis and high-dose intravenous immunoglobulin (IVIg), are often employed for treatment (4). Here, we report a patient with SPS complicated by dysthyroid ophthalmopathy, who received intermittent administrations of rituximab. The patient showed obvious improvement of both SPS and dysthyroid ophthalmopathy after starting this treatment, and we focus upon the usefulness of rituximab in both disorders with regard to clinical efficacy and safety.

Case Report

A 59-year-old woman noticed muscle stiffness with sudden-onset spasms mainly in lower extremities with no precipitating cause or significant family history while being treated for Graves’ disease in a neighboring hospital. At age 62 she started to use insulin for treatment of DM with the anti-GAD antibody. She gradually became unable to walk because of frequent muscle spasms in her lower extremities. At age 66 she suddenly complained of diplopia, and was referred to our hospital. On admission physical examination showed diffuse goiter, bilateral mild exophthalmos, limited downward movement in the left eye and marked rigidity in the abdomen, lower back and both legs. Muscle power and deep tendon reflexes were normal with no fasciculation, and pathological reflexes were negative. The muscle stiffness score of SPS (4) and clinical activity score of dysthyroid ophthalmopathy (5) were 3 and 1, respectively. Sudden-onset muscle spasms lasting approximately 5 minutes...
mainly in both legs appeared several times a day, particularly on emotional stress. She could not perform routine daily activities by herself because of anxiety-triggered spasms and frequent falls. There were no abnormal findings in routine laboratory data, including urinalysis, hematology, renal and hepatic indices, and electrolytes except for hemoglobin A1c (6.8%, normal 4.3-5.8%). Free T3 and T4 were 4.56 pg/mL (normal 2.3-4.0 pg/mL) and 1.54 ng/dL (normal 1.0-2.0 ng/dL), respectively, and thyroid function was well controlled by levothyroxine and thiamazole. Marked elevation was seen in the anti-thyroglobulin antibody (TGAb, 7,842 IU/mL, normal ≤10.0), anti-thyroid peroxidase antibody (TPOAb, 3,942 IU/mL, normal ≤10.0), anti-thyroid stimulating hormone receptor antibody (TRAb, 87.8%, normal ≤15), thyroid-stimulating antibody (TSAb, 3,850%, normal <180%) and anti-GAD antibody (19,900 U/mL, normal <1.5 U/mL). Electromyography demonstrated spontaneous motor unit activities, which transiently disappeared right after intravenous administration of diazepam (Fig. 1). Magnetic resonance imaging (MRI) demonstrated hypertrophy with gadolinium enhancement in ocular muscles, particularly in the left eye (Fig. 2A).

To ameliorate sudden-onset spasms and diplopia, the patient was treated with IVIg (0.4 g/kg/day for 5 days) repeated 3 times at an interval of 1 month after plasmapheresis in addition to conventional muscle relaxants, including diazepam, baclofen, and alprazolam. Gait disturbance due to muscle spasms improved slightly in conjunction with a decrease in the anti-GAD antibody, but the efficacy did not continue for longer than 6 weeks. No improvement was seen in diplopia. Six months later the anti-CD20 monoclonal antibody, rituximab, was administered intravenously at a dose...
After starting administration of rituximab, the patient showed obvious decreases in the muscle stiffness score of SPS (Fig. 3B) and clinical activity score of dysthyroid ophthalmopathy (Fig. 3C) following quick complete depletion of CD20-positive cells in peripheral blood (Fig. 3A). The anti-GAD antibody, TGAb and TPOAb decreased from approximately 6 weeks after the administration of rituximab (Figs. 3B, 3C), while the TRAb showed no obvious change.

MRI demonstrated reduction in size of ocular muscles with disappearance of gadolinium enhancement (Fig. 2B). Three months later rituximab was additionally given at the same dose as the first administration 2 times at an interval of 1 month because of a slight increase in the frequency of muscle spasms. The anti-GAD antibody, TGAb and TPOAb remained at low levels, and TRAb also decreased gradually. Five months after the third administration of rituximab muscle spasms almost completely disappeared, and the stiffness score of SPS and clinical activity score of dysthyroid oph-
thalamopathy were 1 and 0, respectively. She became able to walk by herself again. No improvement was seen in insulin-dependent DM. There were no serious adverse events other than mild pneumonia due to *Pneumocystis jiroveci* infection, which immediately recovered in response to sulfamethoxazole/trimethoprim. She has remained in good neurological condition with low levels of autoantibodies for 8 months since the third administration of rituximab. The total follow-up period from referral to our hospital is 23 months.

### Discussion

The present patient was diagnosed as having SPS based on muscle stiffness with sudden-onset systemic spasms, spontaneous motor unit activities on electromyography, and strongly positive results for the anti-GAD antibody in serum (1). SPS sometimes develops as a paraneoplastic syndrome (6-8), but there was no evidence suggestive of associated malignancies in the present patient despite intensive systemic survey. Insulin-dependent DM and diplopia due to limited downward movement in the left eye appeared 3 and 7 years after onset of SPS, respectively. Considering that the present patient had hypertrophy of ocular muscles on MRI and Graves’ disease with some anti-thyroid autoantibodies, such as TGAb and TRAb, dysthyroid ophthalmopathy was considered to be the cause of diplopia.

Both SPS and dysthyroid ophthalmopathy are usually treated with immunomodulatory therapies, including corticosteroid and plasmapheresis. In the present patient, however, corticosteroid was inadequate because of associated insulin-dependent DM, and the clinical efficacy of plasmapheresis and IVIg was transient. As B-lymphocytes play an important role in the pathogenesis of SPS and dysthyroid ophthalmopathy with regard to production of autoantibodies (1, 4, 9), we decided to use rituximab for treatment of the present patient. This drug is a humanized chimeric anti-CD20 monoclonal antibody capable of killing CD20-positive cells by complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity and direct induction of apoptosis (10, 11). CD20 is expressed on the surface of pre-B- and mature B-lymphocytes (12), and rituximab shows no direct effects on plasma cells producing immunoglobulins. This drug has been reported to show a favorable outcome in the treatment of malignant lymphoma and autoimmune diseases, including SPS and dysthyroid ophthalmopathy (9, 13-17). In the present patient also, intermittent administrations of rituximab produced obvious improvement of both SPS and dysthyroid ophthalmopathy with a persistent decrease in the anti-GAD and anti-thyroid antibodies. According to the recommended therapeutic protocol for autoimmune disorders, including dysthyroid ophthalmopathy, rituximab is usually given twice at an interval of 2 weeks (13, 14), but in the present patient a single administration was performed at her request. As the frequency of muscle spasms slightly increased 3 months later, rituximab was given again. The interval of approximately 6 weeks between disappearance of CD20-positive cells from peripheral blood and a decrease in the serum autoantibodies may be due to the lack of direct effects of rituximab on plasma cells. No serious adverse events occurred during and after the treatment in the present patient except for mild pneumonia due to *Pneumocystis jiroveci*, although rituximab has been recently reported to occasionally induce a fatal disease due to infection, such as progressive multifocal leukoencephalopathy (18, 19). We plan to readminister this drug if the frequency of muscle spasms increases again.

There are 2 notable points in the present patient. One is that rituximab failed to ameliorate insulin-dependent DM, in which autoimmune mechanisms play a central role in the pathogenesis as seen in SPS. Decreased production of γ-aminobutyric acid by the anti-GAD antibody causes reversible impairment in function of inhibitory neurons mainly in the spinal cord, leading to spontaneous activities of the motor unit in SPS (2, 3). In contrast to that, insulin-dependent DM has been reported to histopathologically show approximately 80% loss of islet cells in the pancreas, particularly β-cells, at onset of hyperglycemia (20). The discrepancy in response to the rituximab therapy between SPS and insulin-dependent DM may be due to these different pathogenetic mechanisms. The other notable point is that the anti-GAD and anti-thyroid antibodies are not necessarily correlated with disease activity of SPS and dysthyroid ophthalmopathy, respectively. Particularly in SPS in the present case, sudden-onset spasms obviously improved soon after administration of rituximab, although the anti-GAD antibody still remained at a high serum level. These findings suggest that the clinical effectiveness of rituximab in SPS and dysthyroid ophthalmopathy may be not only due to decreased concentrations of autoantibodies but also to other immune-mediated mechanisms, such as inhibition of antigen presentation and cytokine production by B cells. Several recent reports showing a lack of correlation between clinical activity of dysthyroid ophthalmopathy and autoantibodies in serum after rituximab therapy also support this hypothesis (13, 14). The remaining autoantibodies after rituximab therapy in the present patient probably have no significant pathogenicity as long as the titer stays at a low serum level.

In summary, rituximab might be useful in the treatment of SPS with regard to efficacy and safety, although the precise mechanisms remain unclear. This drug should be considered as a potent therapeutic option in refractory patients with SPS, particularly when concurrent with associated disorders, such as dysthyroid ophthalmopathy.

### Acknowledgement

This work was supported by a grant from Neuroimmunological Disease Division of the Ministry of Public Health, Labor and Welfare, Japan.
References


© 2010 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imindex.html